Tisdag 6 Maj | 22:28:39 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-05 08:00 Kvartalsrapport 2025-Q3
2025-08-20 08:00 Kvartalsrapport 2025-Q2
2025-05-15 N/A X-dag ordinarie utdelning SPAGO 0.00 SEK
2025-05-14 N/A Årsstämma
2025-05-07 08:00 Kvartalsrapport 2025-Q1
2025-02-06 - Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-06-11 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2024-06-10 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-07 - Bokslutskommuniké 2023
2023-11-03 - Kvartalsrapport 2023-Q3
2023-10-31 - Extra Bolagsstämma 2023
2023-07-31 - Kvartalsrapport 2023-Q2
2023-05-11 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2023-05-10 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-02 - Bokslutskommuniké 2022
2022-11-08 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2022-05-18 - Årsstämma
2022-04-27 - Kvartalsrapport 2022-Q1
2022-02-02 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2021-05-05 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-02 - Bokslutskommuniké 2020
2021-01-15 - Extra Bolagsstämma 2021
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-24 - Kvartalsrapport 2020-Q2
2020-05-29 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2020-05-28 - Årsstämma
2020-04-29 - Kvartalsrapport 2020-Q1
2020-01-30 - Bokslutskommuniké 2019
2019-11-13 - Extra Bolagsstämma 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-05-09 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2019-05-08 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-01-30 - Bokslutskommuniké 2018
2018-11-08 - Kvartalsrapport 2018-Q3
2018-08-27 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2018-05-16 - Årsstämma
2018-04-25 - Kvartalsrapport 2018-Q1
2018-02-14 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-09-22 - Extra Bolagsstämma 2017
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-18 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2017-05-17 - Årsstämma
2017-04-26 - Kvartalsrapport 2017-Q1
2017-02-14 - Bokslutskommuniké 2016
2016-11-08 - Kvartalsrapport 2016-Q3
2016-08-26 - Kvartalsrapport 2016-Q2
2016-05-12 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2016-05-11 - Årsstämma
2016-04-27 - Kvartalsrapport 2016-Q1
2016-02-12 - Bokslutskommuniké 2015
2015-11-12 - Extra Bolagsstämma 2015
2015-11-06 - Kvartalsrapport 2015-Q3
2015-08-27 - Kvartalsrapport 2015-Q2
2015-05-06 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2015-05-05 - Årsstämma
2015-04-29 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-27 - Kvartalsrapport 2014-Q2
2014-04-30 - X-dag ordinarie utdelning SPAGO 0.00 SEK
2014-04-29 - Årsstämma
2014-04-29 - Extra Bolagsstämma 2014
2014-04-29 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-10-29 - Kvartalsrapport 2013-Q3
2013-08-29 - Kvartalsrapport 2013-Q2
2013-05-24 - Kvartalsrapport 2013-Q1
2013-04-25 - Årsstämma
2013-02-22 - Bokslutskommuniké 2012

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Spago Nanomedical är verksamt inom bioteknik. Bolaget utvecklar nanomedicin för diagnostik och behandling av livshotande sjukdomar. Bolagets huvudsakliga verksamhet är inriktad mot att utveckla ett cancerselektivt kontrastmedel för magnetisk resonanstomografi (MR), samt en produkt för radionuklidbehandling av cancer. Båda dessa projekt är baserade på egenutvecklade nanomaterial. Störst verksamhet återfinns inom den nordiska marknaden.
2022-05-18 16:55:00

The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 18, 2022, at which the AGM resolved to approve the income statement and balance sheet for 2021 and discharge the Board members and the CEO from liability for the financial year 2021.

The following resolutions were also passed at the AGM:

Disposition of results
In accordance with the Board's proposal, no dividend will be paid and KSEK 59,211 are carried forward.

Election of board and board fees
The Board shall consist of five ordinary members and no deputies. Peter Leander, Sten Nilsson, Kari Grønås, Eugen Steiner and Nicklas Westerholm were re-elected as members of the Board for the period until the end of the next AGM. Eugen Steiner was re-elected Chairman of the Board.

Board fees for the period until the end of the next AGM shall be SEK 200,000 (unchanged) to the Chairman of the Board and SEK 95,000 (unchanged) to each of the other Board members.

Election of auditor and auditor fee
In accordance with the Nomination Committee's proposal, BDO Mälardalen AB was re-elected as auditor for the period until the end of the AGM in 2023. Authorized Public Accountant Jörgen Lövgren will be primarily responsible for the audit. Fees to the auditor shall be paid in accordance with approved invoices.

Instructions for the nomination committee
The AGM resolved on instructions for the Nomination Committee's work and composition in accordance with the proposal presented in the notice convening the AGM.

Resolution on amendment of the Articles of Association
The AGM resolved, in accordance with the Board's proposal, to increase the limits for the number of shares and the share capital in the Articles of Association (§ 4 and § 5)

Authorization for the Board to resolve to issue new shares
For the period until the next AGM, the Board was authorized to, on one or more occasions, resolve to issue new shares by cash payment, non-cash payment or payment by set-off. By resolutions based on the authorization to issue new shares, issues of shares without deviation from the shareholders’ preferential rights may be up to, in total, as many shares as fall within the limits of the articles of Association at the time of exercise of the authorization. By resolutions based on the authorization to issue new shares, issues of shares with deviation from the shareholders’ preferential rights may be up to, in total a maximum of 20 percent of the total number of shares at the time of exercising the authorization the first time.